Empagliflozin and Linagliptin (Glyxambi)
Questions a plan sponsor actually asks.
What is Empagliflozin and Linagliptin used for?
Empagliflozin and Linagliptin is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Empagliflozin and Linagliptin?
No. Empagliflozin and Linagliptin is brand-only with no generic equivalents currently in market.
How much does my plan pay for Empagliflozin and Linagliptin?
Across 329 Part D plans, Empagliflozin and Linagliptin averages $11.22/unit (NADAC). Lowest available: $11.20/unit. Highest in distribution: $11.24/unit.
Is Empagliflozin and Linagliptin on the FDA shortage list?
No. Empagliflozin and Linagliptin is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.